Perlecan Domain V Induces VEGf Secretion in Brain Endothelial Cells through Integrin α5β1 and ERK-Dependent Signaling Pathways

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Clarke, Douglas N ^a,b   Al Ahmad, Abraham ^a   Lee, Boyeon ^a   Parham, Christi ^a   Auckland, Lisa ^a   Fertala, Andrezj ^c   Kahle, Michael ^a,d   Shaw, Courtney S ^a   Roberts, Jill ^d   Bix, Gregory J ^d  

^a TEXAS A M COLLEGE OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSAMINOGLYCAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INITIATION FACTOR 4E; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; RECOMBINANT PERLECAN DOMAIN V; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VERY LATE ACTIVATION ANTIGEN 5;

AMINO ACID SEQUENCE; ANGIOGENESIS; ANIMAL CELL; ARTICLE; BRAIN CELL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG PURIFICATION; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; MICROVASCULAR ENDOTHELIAL CELL; MOUSE; NERVE CELL CULTURE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SECRETION; RAT; SIGNAL TRANSDUCTION;

ANIMALS; BRAIN; BUTADIENES; CELL PROLIFERATION; CELLS, CULTURED; CHROMONES; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; EUKARYOTIC INITIATION FACTOR-4E; GENE EXPRESSION REGULATION; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INTEGRIN ALPHA5BETA1; MAP KINASE SIGNALING SYSTEM; MICE; MORPHOLINES; NITRILES; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84866460601     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045257     Document Type: Article

References (49)

1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, et al. (2012) Executive summary: Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 125: 188-97.
2. Grotta J, Jacobs T, Koroshetz W, Moskowitz M, (2008) Stroke Program Review Group: An Interim Report. Stroke 39: 1364-1370.
3. del Zoppo G, Milner R, (2006) Integrin-matrix interactions in the cerebral microvasculature. Arterioscler Thromb Vasc Biol 25: 1966-1975.
4. Fukuda S, Fini CA, Mabuchi T, Koziol JA, Eggleston LL Jr, et al. (2004) Focal Cerebral Ischemia Induces Active Proteases That Degrade Microvascular Matrix. Stroke 35: 998-1004.
5. Milner R, Hung S, Erokwu B, Dore-Duffy P, LaManna JC, et al. (2008) Increased expression of fibronectin and the α5β1 integrin in angiogenic cerebral blood vessels of mice subject to hypobaric hypoxia. Molecular Cellular Neuroscience 38: 43-52.
6. Mundel TM, Kalluri R, (2007) Type IV collagen-derived angiogenesis inhibitors. Microvascular Research 74: 85-89.
7. Bix G, Iozzo RV, (2005) Matrix revolutions: "tails" of basement-membrane components with angiostatic functions. Trends Cell Biol 15: 52-60.
8. Bix G, Iozzo R, (2008) Novel interactions of perlecan: unraveling perlecan's role in angiogenesis. Micro Res Techniq 71: 339-348.
9. Mongiat M, Sweeney S, San Antonio JD, Fu J, Iozzo RV, (2003) Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan. J Biol Chem 278: 4238-4249.
10. Bix G, Castello R, Burrows M, Zoeller JJ, Weech M, et al. (2006) Endorepellin in vivo: targeting the tumor vasculature and retarding cancer growth and metabolism. J Natl Cancer Inst 98: 1634-1646.
11. Bix G, Fu J, Gonzalez E, Macro L, Barker A, et al. (2004) Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through the a2b1 integrin. J Cell Biol 166: 97-109.
12. Woodall BP, Nystrom A, Iozzo RA, Eble JA, Niland S, et al. (2008) Integrin α2β1 Is the Required Receptor for Endorepellin Angiostatic Activity. Journal of Biological Chemistry 283: 2335-2343.
13. Issbrucker K, Marti HH, Hippenstiel S, Springmann G, Voswinckel R, et al. (2003) p38 MAP kinase-a molecular switch between VEGF-induced angiogenesis and vascular hyperpermeability. FASEB J 17: 262-4.
14. Lee B, Clarke D, Al Ahmad A, Kahle M, Parham C, et al. (2011) Perlecan domain V is neuroprotective and pro-angiogenic following ischemic brain stroke in rodents. JCI 121: 3005-3023.
15. Saini M, Pinteaux E, Lee B, Bix G, (2011) Oxygen-glucose deprivation and interleukin-1a trigger the release of perlecan LG3 by cells of neurovascular unit. J Neurochem 119: 760-771.
16. Gonzalez EM, Reed CC, Bix G, Fu J, Zhang Y, et al. (2005) BMP-1/Tolloid-like metalloproteases process endorepellin, the angiostatic C-terminal fragment of perlecan. J Biol Chem 280: 7080-7087.
17. Cailhier JF, Sirois I, Laplante P, Lepage S, Raymond MA, et al. (2008) Caspase-3 activation triggers extra-cellular cathepsin L release and endorepellin proteolysis. Journal of Biological Chemistry 27220-27229.
18. Wang J, Milner R, (2006) Fibronectin promotes brain capillary endothelial cell survival and proliferation through α5β1 and α5β3 integrins via MAP kinase signalling. Journal of Neurochemistry 96: 148-159.
19. McGeer PL, Zhu SG, Dedhar S, (1990) Immunostaining of human brain capillaries by antibodies to very late antigens. Journal of Neuroimmunology 26: 213-218.
20. Noonan DM, Fulle A, Valente P, Cai S, Horigan E, et al. (1991) The complete sequence of perlecan, a basement membrane heparan sulfate proteoglycan, reveals extensive similarity with laminin A chain, low density lipoprotein-receptor, and the neural cell adhesion molecule. J Biol Chem 266: 22939-22947.
21. Murdoch AD, Dodge GR, Cohen I, Tuan RS, Iozzo RV, (1992) Primary structure of the human heparan sulfate proteoglycan from basement membrane (HSPG2/perlecan). A chimeric molecule with multiple domains homologous to the low density lipoprotein receptor, laminin, neural cell adhesion molecules, and epidermal growth factor. J Biol Chem 267: 8544-8557.
22. Curnis F, Sacchi A, Gasparri A, Longhi R, Bachi A, et al. (2008) Isoaspartate-Glycine-Arginine: A New Tumor Vasculature-Targeting Motif. Cancer Res 68: 7073-7082.
23. Corti A, Curnis F, Arap W, Pasqualini R, (2008) The neovasculature homing motif NGR: more than meets the eye. Blood 112: 2628-2635.
24. Zimmermann S, Moelling K, (1999) Phosphorylation and regulation of Raf by Akt. Science 286: 1741-1744.
25. Aksamitiene E, Kholodenko BN, Kolch W, Hoek JB, Kiyatkin A, (2010) PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells. Cell Signal 22: 1369-1378.
26. Fischer S, Wobben M, Marti HH, Renz D, Schaper W, (2002) Hypoxia-induced hyperpermeability in brain microvessel endothelial cells involves VEGF-mediated changes in the expression of zonula occludens-1. Microvascular Res 63: 70-80.
27. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, et al. (1996) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380: 439-442.
28. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, et al. (1996) Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380: 435-439.
29. Serebriskii I, Castello-Cros R, Lamb A, Golemis ECE, (2008) Fibroblast-derived 3D matrix differentially conditions the growth and drug-responsiveness of human cancer cells. Matrix Biol 27: 573-578.
30. Hermann DM, Zechariah A, (2009) Implications of vascular endothelial growth factor for postischemic neurovascular remodeling. J Cereb Blood Flow Metab 29: 1620-1643.
31. Sun Y, Jin K, Xie L, Childs J, Mao XO, et al. (2003) VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J Clin Invest 111: 1843-1851.
32. Ferrara N, Gerber HP, LeCouter J, (2003) The biology of VEGF and its receptors. Nat Med 9: 669-676.
33. Zhang ZG, Zhang L, Jiang Q, Zhang R, Davies K, et al. (2000) VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest 106: 829-838.
34. Kilic E, Kilic U, Wang Y, Bassetti CL, Marti HH, et al. (2006) The phosphatidylinositol-3 kinase/Akt pathway mediates VEGF's neuroprotective activity and induces blood brain barrier permeability after focal cerebral ischemia. FASEB J 20: 1185-1187.
35. Wang Y, Kilic E, Kilic U, Weber B, Bassetti CL, et al. (2005) VEGF overexpression induces post-ischaemic neuroprotection, but facilitates haemodynamic steal phenomena. Brain 128: 52-63.
36. Curnis F, Longhi R, Crippa L, Cattaneo A, Dondossola E, et al. (2006) Spontaneous Formation of L-Isoaspartate and Gain of Function in Fibronectin. Journal of Biological Chemistry 281: 36466-36476.
37. Xu J, Maurer L, Hoffman B, Annis D, Mosher DF, (2010) IsoDGR sequences do not mediate binding of fibronectin N-terminal modules to adherent fibronectin-null fibroblasts. J Biol Chem 285: 8563-8571.
38. Troup S, Njue C, Kliewer EV, Parisien M, Roskelley C, et al. (2003) Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. Clin Cancer Res 9: 207-214.
39. Kilic E, Kilic U, Soliz J, Bassetti CL, Gassmann M, et al. (2005) Brain-derived erythropoietin protects from focal cerebral ischemia by dual activation of ERK-1/-2 and Akt pathways. FASEB J 19: 2026-2028.
40. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, et al. (2002) Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin. Mol Cell Biol 22: 7004-7014.
41. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, et al. (2000) Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Research 60: 1541-1545.
42. Ryu MH, Park HM, Chung J, Lee CH, Park HR, (2010) Hypoxia-inducible factor-1α mediates oral squamous cell carcinoma invasion via upregulation of α5 integrin and fibronectin. Biochem Biophys Res Commun 393: 11-5.
43. Textor B, Sator-Schmitt M, Richter KH, Angel P, Schorpp-Kistner M, (2006) c-Jun and JunB are essential for hypoglycemia-mediated VEGF induction. Ann N Y Acad Sci 1091: 310-318.
44. Yu B, Miao ZH, Jiang Y, Li MH, Yang N, et al. (2009) c-Jun protects hypoxia-inducible factor-1α from degradation via its oxygen-dependent degradation domain in a nontranscriptional manner. Cancer Res 69: 7704-7712.
45. Alfranca A, Gutierrez MD, Vara A, Aragones J, Vidal F, et al. (2002) c-Jun and hypoxia-inducible factor 1 functionally cooperate in hypoxia-induced gene transcription. Mol Cell Biol 22: 12-22.
46. Sapatino B, Welsh C, Smith C, Bebo B, Linthicum D, (1993) Cloned mouse cerebrovascular endothelial cells that maintain their differentiation markers for Factor VIII, low density lipoprotein and angiotensin-converting enzyme. In Vitro Cell Dev Biol 29A: 923-928.
47. Brittingham R, Colombo M, Ito H, Steplewski A, Birk DE, et al. (2005) Single amino acid substitutions in procollagen VII affect early stages of assembly of anchoring fibrils. J Biol Chem 280: 191-198.
48. Myszka DG, Morton TA, (1998) CLAMP: a biosensor kinetic data analysis program. Trends Biochem Sci 23: 149-190.
49. Bix GJ, Clark GD, (1998) Platelet-Activating Factor Receptor Stimulation Disrupts Neuronal Migration In Vitro. J Neurosci 18: 307-318.